Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for mKRAS drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | mKRAS Mutant Proteins (G12C, G12D, G12V, etc.) High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View mKRAS Products |
| Gene Delivery | mKRAS Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View mKRAS Products |
| Benchmark Ab | Anti-mKRAS Reference Antibody Recombinant positive control for assay standardisation. |
View mKRAS Products |
| Validator | mKRAS siRNA Set For knockdown verification in functional assays. |
View mKRAS Products |
| Related Target A | SOS1 Critical guanine nucleotide exchange factor (GEF) for combination therapies. |
View SOS1 Products |
| Related Target B | SHP2 Key upstream node often targeted to bypass mKRAS resistance. |
View SHP2 Products |
| Related Target C | EGFR Upstream RTK; critical for combination therapy and resistance studies. |
View EGFR Products |
| Related Target D | NRAS RAS isoform for selectivity counter-screening and off-target profiling. |
View NRAS Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Mutant vs WT Selectivity Profiling | Comprehensive panel of mKRAS mutants and WT KRAS proteins available with >95% purity for strict SPR/BLI counter-screening. |
| State-Dependent Drug Binding (ON/OFF) | Recombinant proteins functionally compatible with GTP/GDP loading assays; native folding maintained. |
| Secondary Resistance Screening | Sequence verified double-mutants (e.g., G12C/Y96D) tailored for next-generation inhibitor validation. |
| False Positives in Cellular Assays | Validated siRNA included for precise specificity checks and target-dependency validation. |
| Isoform Cross-reactivity (KRAS / NRAS / HRAS) | Homolog panel (KRAS, NRAS, HRAS) strictly verified by mass spec; Endotoxin controlled. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) for mutant-specific detection. |
Live mKRAS R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for mKRAS therapeutics is intensifying, with major players shifting focus from traditional G12C-specific small molecules to pan-KRAS inhibitors and targeted degraders (PROTACs). As first-generation therapies reach the clinic and encounter acquired resistance via secondary mutations or upstream pathway activation, the next wave of R&D is heavily targeting non-covalent mechanisms, active-state (GTP-bound) inhibitors, and synergistic combination regimens to ensure durable patient responses.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (Covalent) | Amgen, Mirati (BMS) | NSCLC, CRC (G12C) | Covalent Binding Kinetics (Need high-purity intact proteins for MS/SPR) |
| Small Molecule (Non-Covalent / Pan-KRAS) | Revolution Medicines, Boehringer Ingelheim | Pancreatic Cancer, Solid Tumors | Selectivity Assay (Need diverse mutant panels vs WT and HRAS/NRAS) |
| PROTAC / Molecular Glues | Arvinas, Cullgen | Refractory Solid Tumors | Ternary Complex Validation (Need E3 ligase and target proteins) |
| TCR-T / Cancer Vaccines | Moderna, Elicio Therapeutics | Advanced KRAS+ Cancers | Epitope Presentation (Need Sequence Verified antigens for immune screening) |
Molecular Differentiation & Assay Strategy
To develop best-in-class mKRAS drugs, differentiation is required in the following dimensions, matched with precise assay validation:
1. Absolute Selectivity (Mutant vs. WT / Isoform)
- Need: KRAS is essential for normal cell proliferation; drugs must spare WT KRAS and avoid inhibiting NRAS/HRAS to prevent systemic toxicity. For covalent inhibitors, binding to GTP-bound (active) vs. GDP-bound (inactive) states must be distinguished.
- Assay Strategy: Use mutant and WT KRAS proteins for SPR/BLI affinity comparison; verify covalent adduct formation by Mass Spec; use NRAS/HRAS homolog panels for off-target biochemical screening.
2. Binding Mechanism & Residence Time
- Need: The Switch II pocket is shallow and highly dynamic; non-covalent inhibitors require long residence time or high local concentration; covalent drugs need assessment of reaction kinetics and cysteine selectivity.
- Assay Strategy: Cellular Thermal Shift Assay (CETSA) and TSA; ITC for thermodynamic parameters; GTPase activity inhibition assay for functional blockade.
3. Cellular Permeability & Subcellular Localization
- Need: KRAS is anchored to the inner cell membrane; drugs must penetrate the cell membrane and enrich in the correct subcellular compartment.
- Assay Strategy: Construct lentivirus stable overexpression cell lines (e.g., membrane localization reporter systems or fluorescent fusion proteins) combined with high-content imaging to assess compound binding at the inner cell membrane.
4. Resistance Surveillance & Mutation Coverage
- Need: Best-in-class drugs must have clear activity data against major mutations (G12C, G12D, G12V, G13D, Q61H) or precisely delineate the resistance profile.
- Assay Strategy: Expanded mutant panel including secondary resistance mutants (e.g., G12C/Y96D) for biochemical and cellular testing.